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There is a wide variation and lack of evidence in current recommendations for atropine dosing schedules leading to subsequent variation in clinical practice. Therefore, we sought to examine the safety and effectiveness of a titrated vs. ad hoc atropine treatment regimen in a cohort of patients with acute cholinesterase inhibitor pesticide poisoning. A prospective cohort study was conducted in three district secondary referral hospitals in Sri Lanka using a structured data collection form that collected details of clinical symptoms and outcomes of cholinesterase inhibitor pesticide poisoning, atropine doses, and signs of atropinization. We compared two hospitals that used a titrated dosing protocol based on a structured monitoring sheet for atropine infusion with another hospital using an ad hoc regime. During the study, 272 symptomatic patients with anticholinesterase poisoning requiring atropine were admitted to the three hospitals. Outcomes of death and ventilation were analyzed for all patients, 226 patients were prospectively assessed for atropine toxicity. At baseline, patients in the titrated dose cohort had clinical signs consistent with greater tox-icity. This in part may be due to ingestion of more toxic organophosphates. They received less pralidoxime and atropine, and were less likely to develop features of atropine toxicity, such as delirium (1% vs. 17%), hallucinations (1% vs. 35%), or either (1% vs. 35%) and need for patient restraint (3% vs. 48%) compared with the ad hoc dose regime. After adjusting for the pesticides ingested, there was no difference in mortality and ventilatory rates between protocols. Ad hoc high dose atropine regimens are associated with more frequent atropine toxicity without any obvious improvement in patient outcome compared with doses titrated to clinical effect. Atropine doses should be titrated against response and toxicity. Further education and the use of a structured monitoring sheet may assist in more appropriate atropine use in anticholinesterase pesticide poisoning.
Introduction
In developing countries, the majority of deaths from self-poisoning are due to cholinesterase-inhibiting insecticides, such as organophosphorus (OP), and carbamate compounds. 1 The number of intoxications is estimated at 3,000,000 per year and the casu-alties around 300,000 per year. 2 Despite antimuscarinic agents, such as atropine, being universally accepted as the cornerstone of treatment, there are no standard treatment protocols, and there are over 31 different recommendations in 38 texts. 3 Despite this variation, there is consensus that adequate atropinization is achieved when the peripheral muscarinic symptoms of bronchial hypersecretion is controlled and cardiovascular function stabilized. Other endpoints include control of bradycardia, absence of sweating and reversal of miosis. Atropine also has central therapeutic effectsanimal studies suggest that atropine may reduce centrally mediated respiratory failure. 4 Comparative studies of different protocols have not been made to guide clinicians. South Asian Clinical Toxicology Research Collaboration (SACTRC) works in partnership with local physicians in Sri Lanka to conduct clinical trials in a number of clinical research centers. In this context, we have observed considerable variation in the use of atropine within Sri Lanka.
We were requested to assess the atropine use in a hospital where we had recently commenced clinical research. Atropine use in this center was without a fixed protocol. At other research centers established over the last 4 years, SACTRC has promoted an atropine protocol that is tailored to clinical response using a structured monitoring sheet. 5 We aimed to compare effectiveness and adverse effects in patients treated with a titrated atropine protocol with those treated with an ad hoc dosing regime.
Methods
This study was part of a larger observational poisoning cohort study that has ethical approval from the Sri Lanka Medical Association and the Australian National University Human Research Ethics Committees.
This was a prospective observational cohort study of symptomatic anticholinesterase insecticide poisoned patients undertaken from February to May 2006. Two hospitals have had a titrated dose atropine protocol with a monitoring sheet actively promoted since 2002. Patients from these hospitals are analyzed together as the 'titrated cohort'. The other hospital had no standard promoted protocol, but the doctors frequently gave boluses and high fixed dose infusions of atropinethis group will be referred to as the ad hoc cohort.
Patients who were prescribed pralidoxime chloride typically received a 1-g bolus followed by further bolus doses of 1 g every 6 h for 1-3 days. The decision to use pralidoxime was made by the treating physician; pralidoxime was not routinely used by one treating physician in the titrated group. Patients known to have taken carbamates received no pralidoxime.
The recommended dosing protocol for symptomatic patients in the titrated atropine cohort has been described more fully. 5 It consists of an initial bolus of 1.5-3 mg of atropine with doses doubling every 5 min until atropinization is achieved. Clearing of chest on auscultation was used as the primary endpoint of atropinization. Following that an infusion is given with a rate that is estimated from the size of the initial dose required to achieve atropinization. This is typically in the range of 1-2 mg/h. The infusion dose is subsequently adjusted up or down depending on the presence of signs of under atropinization (chest signs, sweating, bradycardia and miosis) or over atropinization (absent bowel sounds, fever, tachycardia, mydriasis and confusion). The ad hoc dose cohort received intermittent boluses, infusion or a combination of bolus and infusion as decided by the treating doctors.
Only patients with a history of pesticide ingestion, who had cholinergic features, received atropine were included in the study. The decision to atropinize patients was made by the treating medical team without involvement of the research team. Where possible the type of ingested pesticide was considered confirmed, if the ingested pesticide could be named or if the bottle was presented during the admission. Previous studies have shown this approach to be reliable for identification of the ingested pesticide. 6 Patient demographics, the type and amount of anticholinesterase insecticide, alcohol co-ingestion and other co-morbid conditions, and the major clinical outcomes of death and ventilation were prospectively recorded for all patients.
Additional prospective data collection for atropine effects used a structured data form completed at regular intervals by medically qualified and trained research assistants. A minimum of six and an average of nine data records were taken each day for each patient. Atropine bolus and infusion rates were also recorded. Clinical data included blood pressure, heart rate, respiratory rate, pupil size, bowel sounds, pulmonary signs (i.e. crepitations on auscultation), and presence of auditory and visual hallucinations. Patients were also screened for delirium using Confusion Assessment Method (CAM) (Box 1). Atropine toxicity was defined as atropine induced delirium, hallucinations (which are not a feature of delirium defined by CAM), or both.
Data analysis
Based upon an intention-to-treat principle, analysis for major clinical outcomes, such as death and ventilation, was made for all patients admitted to the hospital, who met the inclusion criteria. Analysis for adverse effects was restricted to those patients, who had prospective sequential observations for 
Results
During the study period ( Figure) , 272 consecutive symptomatic patients with anticholinesterase poisoning were enrolled. Atropine data were collected for 226/272 (83%).
The baseline characteristics of patients in both groups were different (Table 1 ). There were statistical differences in age, sex, and alcohol co-ingestion, with the ad hoc dose group having higher rates of pralidoxime usage and impairment of Glasgow Coma Scale (GCS) (GCS 9-14) on admission. The median time to admission was 4 h and similar in both groups.
The severity of poisoning was worse in the titrated groupthey were more likely to have been transferred and treated with atropine from a peripheral hospital, to have ingested a higher estimated dose of insecticide and clinically had more signs of anticholinesterase poisoning at presentation manifested by higher rates of pulmonary crepitations on admission. The pattern of pesticide ingestion was dissimilar in that the titrated dose group had a lower proportion taking chlorpyrifos and a higher proportion taking dimethoate (Table 1) . The diagnosis of delirium requires a present/ abnormal rating for criteria (1) and (2) with either (3) and (4).Adopted from Inouye, et al. 12 Figure Flow chart of major outcomes following anticholinesterase pesticide poisoning for all patients in the cohort.
Comparison of two commonly practiced atropinization regimens PMS Perera, et al.
The amount of atropine boluses, infusion rates, and total daily doses were significantly higher in the ad hoc dose regimen ( Table 2) . As a consequence, atropine toxicity was significantly more common with the ad hoc regimen ( Table 3 ). The median time to development of atropine toxicity was 7 h (IQR 3-15) following atropinization in all hospitals. The most frequent manifestation was agitated delirium, requiring either physical restraint (tied to bed) or sedation (with diazepam 5-10 mg i.v. or haloperidol 5 mg i.m. prn). In the titrated dose group only 3/126 (2%) patients required any form of restraint. By contrast, 48/100 (48%) of the ad hoc dose group were restrained. The rates of delirium (17% vs. 1%) and hallucinations (35% vs. 1%) or either was significantly higher in the ad hoc dose regime. Moreover, anticholinergic delirium with hallucinations was noted in 36 patients, but only one (1/36; 3%) of these was in the titrated atropine dose group. These patients were noted to have dilated pupils, dry mucosal membranes, flushed skin, and decreased bowel sounds and to have needed urinary catheterization, further strengthening the diagnosis of atropine toxicity. The median duration of hospital stay was significantly shorter in the titrated atropine dose group (Table 3) .
There was no statistical difference in case fatality between groups for either the entire cohort or the subgroup monitored for atropine effect (Table 3) .
Ventilation rates were higher in the titrated atropine group [23% vs. 1%, relative risk 10.62 (95% CI 7.1-15.3), P = < 0.0001]. This difference was due to an excess of dimethoate poisonings in the titrated group and was not seen for other pesticides (Table 4 ). Oxime therapy did not significantly alter the relative risk for ventilation in either group: 0.37 (95% CI 0.043-3.21, P-value = 0.398) and 1.58 (95% 
Discussion
Atropine is the only universally accepted specific treatment in the management of anticholinesterase poisoning. Despite this universal acceptance, there are no data to guide administration with a consequent wide variation in recommendations for dosing. 3 Adherence to some protocols will lead to lengthy delays in time to optimum atropinization, which can result in death from central respiratory depression, hypoxia (due to bronchospasm and bronchorrhoea), and hypotension (due to bradycardia and myocardial depression). 3 Conversely, some protocols may lead to excessive anticholinergic toxicity, which in severe cases may even be fatal. 3 The titrated atropine dose group received significantly lower total doses of atropine. The rates of atropine toxicity, restraint, and the duration of hospital stay were all significantly lower in this group despite having indirect evidence of higher toxicity on admission, as shown by more patients with lung signs of poisoning, higher rates of ventilation and estimated doses of ingestion, and having ingested more dangerous pesticides.
The bolus doses and subsequent infusion rates were higher in the ad hoc atropine dose group. The median time to initiate atropine treatment is 4 h. The fact that atropine toxicity developed a median of 7 h after starting the infusion in both groups suggests that toxicity was due to higher infusion rates. Because the infusions rates in the titrated group are guided by the initial atropinization loading dose (typically 10-20% of the cumulative bolus doses per hour), theoretically this might lead to less toxicity.
There were no significant differences in death rates between the two groups, despite baseline characteristics suggesting that the titrated dose group had a higher risk of death. The ad hoc dose group had predominately ingested chlorpyrifos which has a lower case-fatality ratio (8.0) than most organophosphates. 6 Patients in the titrated group had taken a higher proportion of highly lethal OPs and are more likely to have significant aging at the time of admission. 6 This is particularly the case for dimethoate poisoning with a high case-fatality ratio of 23%. 6 Dimethoate poisoning patients were more ill, unconscious, hemodynamically unstable on admission requiring inotropes and rapidly deteriorated into early respiratory failure and largely belonged to the titrated group.
The lower use of pralidoxime in the titrated dose group was mainly due to local clinical practice based on the lack of documented evidence of its efficacy at these doses of oxime in rural Asia. 7 In addition, the doses of 1 gm q.i.d. is likely to be inadequate for dimethoate ingestions. This study, however, is underpowered to detect a therapeutic effect of pralidoxime although theoretically higher use of oxime should result in a lower atropine requirement.
Although rates of ventilation were significantly higher in the titrated group, there was no difference in ventilatory rates for dimethoate, chlorpyrifos, carbamates, unknown OPs and other types of organophosphorous ingestions.
Despite the high proportion of patients who were admitted after being transferred in the titrated group the median time to admission was similar in both groups. This may be attributed due to a primary delay in transport in the ad hoc dose group as this population come from a mountainous area where transportation is slower.
The impairment in consciousness on admission patients (GCS 9-14) was more frequently found in the ad hoc dose group, although the proportion of patients with severe impairment (GCS <9) was more in the titrated group. The reasons remain unclear but may relate to less pre-transfer and inter-transfer atropine treatment in the ad hoc dose group and ingestion of OPs with higher case fatality ratio in the titrated group.
The incidence of delirium may be a significant clinical issue in situations where resources are scarce as such patients require higher nursing time. Delirium may contribute to increased morbidity. 8, 9 Hyperthermia and physical restraining may further contribute to poor outcomes. Prolonged periods of untreated delirium has been shown to result in longer hospital stays, increased higher short and longterm mortality. 10, 11 Rates of alcohol use were comparable in both groups and seem unlikely to have contributed to such a large difference in delirium.
The CAM has become the most widely used instrument for detection of delirium worldwide, because of both its strong validation results as well as its ease of use, it has a sensitivity of 94-100%, specificity of 90-95%, and high inter-observer reliability. 12 There were 18 patients (9%) in the entire cohort which fulfilled the criterion for delirium according to CAM. However, we had very high rates of hallucinations, suggesting that CAM is not sensitive for anticholinergic delirium or were poorly administered or did not culturally translate.
Poor resources may restrict the ability to titrate doses and may contribute to the evolution of clinical practices of over treatment as a therapeutic goal. Arguably over atropinization may be preferable to under atropinization in some situations, such as transportation, high patient load, or limited monitoring. In this cohort, the protocol associated with high rates of atropine toxicity was not associated with improved mortality, despite the fact they received a higher level of monitoring than they would receive in most secondary hospitals.
A potential limitation of our study was that a large number of patients (129/153; 84%) in the titrated groups had been transferred from a primary hospital. In general, these patients would receive bolus atropine doses prior to transfer although these details on pre-transfer treatment were poorly documented or not available. If this is the case, it would minimize the difference between the initial bolus doses and suggest toxicity being related to higher infusion rates.
Conclusions
This study suggests that there is no therapeutic advantage in over atropinization of patients in situations where the patient can be monitored. Titrated doses of atropine are less likely to cause toxicity. As the infusion rate appears to be associated with anticholinergic toxicity, this study suggests that the maintenance infusion dose should be calculated based on the cumulative dose of atropine used to optimally atropinize the patient on admission. Use of a structured monitoring sheet may aid in tailoring doses to clinical response.
